肺结核后慢性肺曲霉病诊治专家共识

doi:10.19871/j.cnki.xfcrbzz.2024.06.014

摘要/Abstract

摘要： 慢性肺曲霉病是一种起病隐匿、症状不典型的疾病,具有较高的病死率。该病常发生在肺结核治愈后的残存空洞中,由于其症状与肺结核相近,临床上容易发生误诊。由于我国在肺结核后慢性肺曲霉病方面的临床研究数据相对较少,目前尚未制订出一套针对肺结核后慢性肺曲霉病的完整诊治规范。因此,本文参考了国内外的相关指南和共识,组织了结核病学、呼吸病学、感染病学、微生物学、影像学和病理学等多个领域的专家进行了集中研讨,共形成了13条推荐意见,旨在为肺结核后慢性曲霉病患者的规范化诊治和科学管理提供参考。这些推荐意见涵盖了流行病学、循证医学证据和临床诊治等多个方面,以期提高对肺结核后慢性肺曲霉病的诊疗水平,减少误诊和漏诊,改善患者的预后。

关键词: 慢性肺曲霉病, 肺结核后, 治疗, 专家共识, 诊断, 评估

Abstract: Chronic pulmonary aspergillosis (CPA) is a high fatality rate disease with atypical symptoms,and often occurring in residual cavities left after successful tuberculosis treatment. Due to its similar symptoms to tuberculosis, it is easy to be misdiagnosed. In China, a complete set of diagnosis and treatment norms for the post-tuberclulosis chronic pulmonary aspergillosis(post-TB CPA) has not been formulated. Therefore, this consensus referred to the relevant guidelines and consensus both domestically and internationally, organizing a centralized discussion among experts in the fields of tuberculosis, respiratory medicine, infectiology, microbiology, imaging and pathology. They formulated 13 recommendations to provide a reference for the standardized diagnosis and treatment and scientific management of patients with CPA after tuberculosis. These recommendations cover many aspects such as epidemiology, evidence-based medicine, and clinical diagnosis and treatment, aiming to improve the diagnosis and treatment level of post-TB CPA, reduce misdiagnosis and missed diagnosis, and ultimately improve patient outcomes.

Key words: Chronic pulmonary aspergillosis, Post-tuberclulosis, Treatment, Expert consensus, Diagnosis, Assessment

中图分类号:

R521
R519

张培泽, 赵曼曼, 魏方军, 史怀芳, 邓国防, 卢洪洲. 肺结核后慢性肺曲霉病诊治专家共识[J]. 新发传染病电子杂志, 2024, 9(6): 74-84.

Zhang Peize, Zhao Manman, Wei Fangjun, Shi Huaifang, Deng Guofang, Lu Hongzhou. Expert consensus on diagnosis and treatment of the post-tuberclulosis chronic pulmonary aspergillosis[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(6): 74-84.

参考文献

[1] IZUMIKAWA K.Recent advances in chronic pulmonary aspergillosis[J]. Respir Investig, 2016, 54(2): 85-91.
[2] PAGE ID, BYANYIMA R, HOSMANE S, et al.Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation[J]. Eur Respir J, 2019, 53(3): 1801184.
[3] GAGO S, DENNING DW, BOWYER P.Pathophysiological aspects of Aspergillus colonization in disease[J]. Med Mycol, 2019, 57(2): s219-s227.
[4] 郑广平, 张倩倩, 谭卫国, 等. 非活动性肺结核合并肺曲霉菌感染的临床影像分析[J/CD]. 新发传染病电子杂志, 2018, 3(1): 34-36,40.
[5] DENNING DW.Global incidence and mortality of severe fungal disease[J]. Lancet Infect Dis, 2024, 24(7): e428-e438.
[6] DENNING DW, PLEUVRY A, COLE DC.Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis[J]. Bull World Health Organ, 2011, 89(12): 864-872.
[7] OCANSEY BK, OTOO B, GBADAMOSI H, et al.Importance of Aspergillus-Specific Antibody Screening for Diagnosis of Chronic Pulmonary Aspergillosis after Tuberculosis Treatment: A Prospective Follow-Up Study in Ghana[J]. J Fungi (Basel), 2023, 9(1): 26.
[8] HEDAYATI MT, AZIMI Y, DROUDINIAA, et al. Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran[J]. Eur J Clin Microbiol Infect Dis, 2015, 34(9): 1759-1765.
[9] SETIANINGRUM F, ROZALIYANI A, SYAM R, et al.Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia[J]. Diagn Microbiol Infect Dis, 2020, 98(3): 115124.
[10] NGUYEN NTB, LE NGOC H, NGUYEN NV, et al.Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study[J]. J Fungi (Basel), 2021, 7(7): 532.
[11] DENNING DW, CADRANEL J, BEIGELMAN-AUBRY C, et al.Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management[J]. Eur Respir J, 2016, 47(1): 45-68.
[12] 邱晨, 陈普选, 吴诗品. 肺曲霉病临床诊治评析[M]. 肺曲霉病临床诊治评析, 2017.
[13] LYON SM, ROSSMAN MD.Pulmonary Tuberculosis[J]. Microbiol Spectr, 2017, 5(1):e0277121.
[14] 中华人民共和国国家卫生和计划生育委员会.肺结核诊断标准(WS 288—2017)[J/CD].新发传染病电子杂志,2018,3(1):59-61
[15] 国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020 年版)的通知[A/OL]. [2020-06-10]. http://tb.chinacdc.cn/ggl/202004/P020200414515703939844.pdf.
[16] DENNING DW, RINIOTIS K, DOBRASHIAN R, et al.Chronic cavitary and Fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature change, and review[J]. Clin Infect Dis, 2003, 37(3): S265-S280.
[17] DENNING DW, PAGE ID, CHAKAYA J, et al.Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings[J]. Emerg Infect Dis, 2018, 24(8): e171312.
[18] 苏永华, 李赛玉, 陈丽静, 等. 痰液检验对肺曲霉菌病的诊断价值探讨[J]. 中国卫生标准管理, 2017, 8(28): 131-134.
[19] 郑小梅. 痰液检验对肺曲霉菌病的诊断价值分析[J]. 基层医学论坛, 2019, 23(13): 1863-1865.
[20] GODET C, PHILIPPE B, LAURENT F, et al.Chronic Pulmonary Aspergillosis: An Update on Diagnosis and Treatment[J]. Respiration, 2014, 88(2): 162-174.
[21] VAN BRAECKEL E, PAGE I, DAVIDSEN J R, et al.Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement[J]. Eur Respir J, 2022, 59(6): 2102950.
[22] YANG L, SONG J, WANG Y, et al.Metagenomic Next-Generation Sequencing for Pulmonary Fungal Infection Diagnosis: Lung Biopsy versus Bronchoalveolar Lavage Fluid[J]. Infect Drug Resist, 2021, 14: 4333-4359.
[23] 中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10): 754-763.
[24] IZUMIKAWA K, YAMAMOTO Y, MIHARA T, et al.Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis[J]. Med Mycol, 2012, 50(8): 811-817.
[25] SEHGAL I S, DHOORIA S, CHOUDHARY H, et al.Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis[J]. J Clin Microbiol, 2019, 57(3): e01821-18.
[26] DE OLIVEIRA VF, SILVA GD, TABORDA M, et al.Systematic review and meta-analysis of galactomannan antigen testing in serum and bronchoalveolar lavage for the diagnosis of chronic pulmonary aspergillosis: defining a cutoff[J]. Eur J Clin Microbiol Infect Dis, 2023, 42(9): 1047-1054.
[27] LI H, RUI Y, ZHOU W, et al.Role of the Aspergillus-Specific IgG and IgM Test in the Diagnosis and Follow-Up of Chronic Pulmonary Aspergillosis[J]. Front Microbiol, 2019, 10: 1438.
[28] PATTERSON TF, THOMPSON GR, DENNING DW, et al.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): 433-442.
[29] MENG-RUI L, HUNG-LING H, LI-TA K, et al.Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study[J]. J Fungi (Basel), 2021, 7(6): 480.
[30] ANAN K, KATAOKA Y, OKABAYASHI S, et al.Diagnostic accuracy of Aspergillus-specific antibodies for chronic pulmonary aspergillosis: A systematic review and meta-analysis[J]. Mycoses, 2021, 64(7): 701-715.
[31] MA X, WANG K, ZHAO X, et al.Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis[J]. BMC Infect Dis, 2019, 19(1): 694.
[32] SEHGAL IS, DHOORIA S, MUTHU V, et al.An overview of the available treatments for chronic cavitary pulmonary aspergillosis[J]. Expert Rev Respir Med, 2020, 14(7): 715-727.
[33] 国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 《中国防痨杂志》编辑委员会. 肺结核活动性判断规范及临床应用专家共识[J]. 中国防痨杂志, 2020, 42(4): 301-307.
[34] WARRIS A, ARMSTRONG-JAMES D.Antifungal therapy for chronic pulmonary aspergillosis[J]. Lancet Infect Dis, 2022, 22(7): 924-926.
[35] SEHGAL IS, DHOORIA S, MUTHU V, et al.Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India[J]. Lancet Infect Dis, 2022, 22(7): 1052-1061.
[36] BONGOMIN F.Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern[J]. PLoS Pathog, 2020, 16(8): e1008742.
[37] LARKIN PMK, MULTANI A, BEAIRD OE, et al.A Collaborative Tale of Diagnosing and Treating Chronic Pulmonary Aspergillosis, from the Perspectives of Clinical Microbiologists, Surgical Pathologists, and Infectious Disease Clinicians[J]. J Fungi (Basel), 2020, 6(3): 106.
[38] IM Y, JHUN BW, KANG ES, et al.Impact of treatment duration on recurrence of chronic pulmonary aspergillosis[J]. J Infect, 2021, 83(4): 490-495.
[39] SEHGAL IS, DHOORIA S, CHOUDHARY H, et al. Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers[J]. Clin Microbiol Infect, 2019, 25(9): 1157.e1-1157.e7.
[40] VAN KAMPEN SC, WANNER A, EDWARDS M, et al.International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review[J]. BMJ Global Health, 2018, 3(4): e000745.
[41] LAMOTH F, CALANDRA T.Pulmonary aspergillosis: diagnosis and treatment[J]. Eur Respir Rev, 2022, 31(166): 220114.
[42] LAURSEN CB, DAVIDSEN JR, LANDER VAN A, et al.CPAnet Registry—An International Chronic Pulmonary Aspergillosis Registry[J]. J Fungi (Basel), 2020, 6(3): 96.
[43] 刘恒, 邝爱玲, 陈日垦, 等. 慢性肺曲霉病的诊治进展[J]. 国际呼吸杂志, 2016, 36(24): 1910-1913.
[44] CADRANEL J, PHILIPPE B, HENNEQUIN C, et al.Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(11): 3231-3239.
[45] TASHIRO M, TAKAZONO T, SAIJO T, et al.Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis[J]. Clin Infect Dis, 2019, 70(5): 835-842.
[46] VAN INGEN J, VAN DER LEE HA, RIJS T AJ, et al. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands[J]. J Antimicrob Chemother, 2014, 70(1): 178-181.
[47] AGARWAL R, DHOORIA S, SINGH SEHGAL I, et al.A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma[J]. Chest, 2018, 153(3): 656-664.
[48] BONGOMIN F, MAGUIRE N, MOORE CB, et al.Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events[J]. Mycoses, 2019, 62(3): 217-222.
[49] KOSMIDIS C, OTU A, MOORE CB, et al.Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis[J]. Antimicrob Agents Chemother, 2020, 65(1): e01511-20.
[50] 张婷婷, 孙玲洁, 冯四洲. 艾沙康唑治疗侵袭性真菌病的临床研究进展[J]. 中国感染与化疗杂志, 2022, 22(3): 360-365.
[51] BENJELLOUN H, ZAGHBA N, YASSINE N, et al.Chronic pulmonary aspergillosis: A frequent and potentially severe disease[J]. Med Mal Infect, 2015, 45(4): 128-132.
[52] HEINZ WJ, EGERER G, LELLEK H, et al.Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis[J]. Mycoses, 2013, 56(3): 304-310.
[53] KOHNO S, IZUMIKAWA K, KAKEYA H, et al.Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study[J]. Med Mycol, 2011, 49(7): 688-693.
[54] SETIANINGRUM F, ROZALIYANI A, ADAWIYAH R, et al.A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL)[J]. Thorax, 2022, 77(8): 821-828.
[55] MAGHRABI F, DENNING DW.The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach[J]. Curr Fungal Infect Rep, 2017, 11(4): 242-251.
[56] 云彩虹, 周威, 芮昱雯, 等. 手术治疗在慢性肺曲霉病中的作用[J]. 中华结核和呼吸杂志, 2017, 40(10): 780-782.
[57] SHEN C, QIAO G, WANG C, et al.Outcomes of surgery for different types of chronic pulmonary aspergillosis: results from a single-center, retrospective cohort study[J]. BMC Pulmonary Medicine, 2022, 22(1):40.
[58] RUAN H, GONG C, WANG J.The Efficacy and Safety of Surgical Treatment for Patients With Tuberculosis Destroyed Lung With or Without Chronic Pulmonary Aspergillosis[J]. World J Surg, 2021, 45(5): 1595-1601.
[59] LI S, LI Y, LI Z, et al.Loss to follow-up associated factors in patients with chronic pulmonary aspergillosis and its impact on the disease prognosis[J]. Front Public Health, 2022, 10: 1026855.
[60] SEHGAL IS, ARORA K, CORNELY OA, et al.Characterization of Treatment Response Outcomes in Chronic Pulmonary Aspergillosis: CPAnet Definitions Versus the Existing Criteria[J]. Mycopathologia, 2023, 188(5): 721-730.
[61] CADRANEL J, PHILIPPE B, HENNEQUIN C, et al.Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(11): 3231-3239.
[62] SPRUTE R, VAN BRAECKEL E, FLICK H, et al.EQUAL CPA Score 2022: a tool to measure guideline adherence for chronic pulmonary aspergillosis[J]. J Antimicrob Chemother, 2022, 78(1): 225-231.